In this episode, we explore Open Source Drug Discovery 2.0 (OSDD-2) pioneered by Dr. Jake Chen. OSDD-2 represents a groundbreaking framework reimagining how new medicines are developed by combining open collaboration with sustainable commercialization. Designed to counteract rising R&D costs and inefficiency, OSDD-2 integrates AI-powered discovery tools, open-access data, and a hybrid IP model to democratize innovation. The episode introduces the concept of “IP gating,” where early-stage research is conducted collaboratively and transparently. Still, it transitions to limited exclusivity once key milestones are reached—balancing openness with incentives for private investment. Through the example of a project targeting a novel target in Alzheimer’s disease, the discussion highlights how this model could de-risk early research, attract capital for late-stage development, and establish a more equitable and efficient global drug discovery ecosystem. Produced by Dr. Jake Chen.